GE Medical Systems’ planned acquisition of U.K. contrast developer Amersham Health is moving ahead.
The deal has received approval from the European Commission, and has now satisfied all preconditions, according to Waukesha, WI-based GE. U.S. regulatory clearance was granted in December. GE expects the acquisition will close in early April.
By AuntMinnie.com staff writersJanuary 22, 2004
Related Reading
GE Lunar begins Prodigy Advance shipments, December 17, 2003
GE highlights MRI advances, expanded mammography product line, December 2, 2003
Road to RSNA, GE Medical Systems Lunar, November 17, 2003
GE adds to echo offerings, November 10, 2003
GE makes $9.8 billion bid for Amersham, October 10, 2003
Copyright © 2004 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
